Minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products

This guideline applies to human and veterinary medicines.

Current effective version

PDF iconRevision 3 - Adopted guideline

Reference numberEMEA/410/01 Rev. 3
Published29/06/2011
Effective from01/07/2011
KeywordsBovine spongifrom encephalopathy (BSE), transmissible spongiform encephalopathy (TSE), Creutzfeldt-Jakob disease (CJD)
DescriptionThis document provides guidance for minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products. When applicable, read together with PDF iconexplanatory note for medicinal products for human use on the scope of the guideline and PDF iconexplanatory note on the gelatin for use in pharmaceuticals .


Related content for human medicines



Related content for veterinary medicines


How useful was this page?

Add your rating
Average
1 rating